Cyclo Therapeutics (NASDAQ:CYTH) Shares Up 3% – Should You Buy?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) shares shot up 3% on Monday . The stock traded as high as $0.73 and last traded at $0.72. 18,467 shares were traded during trading, a decline of 73% from the average session volume of 68,856 shares. The stock had previously closed at $0.70.

Analyst Ratings Changes

CYTH has been the subject of several recent analyst reports. HC Wainwright reissued a “neutral” rating and issued a $0.95 price objective (down previously from $3.00) on shares of Cyclo Therapeutics in a report on Friday, August 23rd. Ascendiant Capital Markets cut their price objective on Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating for the company in a report on Monday, August 26th. Finally, Maxim Group reissued a “hold” rating on shares of Cyclo Therapeutics in a report on Tuesday, August 27th.

Cyclo Therapeutics Stock Performance

The firm has a fifty day simple moving average of $0.72 and a 200-day simple moving average of $1.03. The firm has a market cap of $20.66 million, a price-to-earnings ratio of -0.80 and a beta of -0.38.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.